ACOG Endorses Updated 2026 Cervical Cancer Screening Guidelines: Key Changes and Implications

Introduction and Context

Cervical cancer, largely preventable through screening and HPV vaccination, remains a significant health concern. The Women’s Preventive Services Initiative (WPSI) periodically reviews evidence to update its recommendations for cervical cancer screening in average-risk individuals. In April 2026, the American College of Obstetricians and Gynecologists (ACOG) issued a Committee Statement qualifiedly endorsing the updated WPSI 2026 guidelines. This update was driven by evolving evidence on screening intervals, the performance of high-risk human papillomavirus (hrHPV) testing (including self-collection), and refined risk stratification. These guidelines aim to maximize early detection while minimizing unnecessary procedures and anxiety, addressing gaps in accessibility and adherence identified in previous protocols.

New Guideline Highlights

The WPSI 2026 guidelines, endorsed by ACOG with specific qualifications, reaffirm a risk-based approach centered on hrHPV testing. The major themes include:

• Primary hrHPV Testing: Remains the preferred strategy for screening average-risk individuals aged 25-65 years.
• Extended Intervals: Confirmation of 5-year screening intervals for those with negative primary hrHPV tests.
• Self-Collection: Formal integration of self-collected vaginal samples for primary hrHPV testing as an option to enhance access and uptake, addressing barriers like discomfort, inconvenience, and healthcare disparities.
• Age-Specific Pathways: Clear, distinct recommendations for individuals aged 21-24, 25-65, and over 65.
• Cessation Criteria: Defined criteria for when screening can safely stop.

Key takeaways for clinicians: Shift focus strongly towards hrHPV testing, embrace self-collection as a crucial tool for equity, and utilize precise risk-based management algorithms.

Updated Recommendations and Key Changes

The 2026 guidelines refine previous versions, particularly the 2021 updates. Key changes include:

Recommendation	WPSI 2021	WPSI 2026 (Endorsed by ACOG)
Primary Screening Strategy (Age 25-65)	Preferred: Primary hrHPV testing every 5 years. Acceptable: Cytology alone every 3 years or Cotesting (cytology + hrHPV) every 5 years.	Preferred: Primary hrHPV testing every 5 years. Cytology alone (every 3 years) or Cotesting (every 5 years) are no longer recommended as routine options for average-risk screening.
Self-Collection for hrHPV Testing	Not addressed as a primary screening method.	Formally incorporated as an acceptable method for primary hrHPV screening to increase access and adherence (ACOG qualification: Requires specific validated assays and robust patient support/education systems).
Screening Age to Start	Begin screening at age 21.	Begin screening at age 25 (unless HIV-positive or otherwise immunocompromised). Screening aged 21-24 is only for those who initiated screening prior to guideline update or specific high-risk scenarios.
Screening Age to Stop	Stop at age 65 if adequate negative prior screening and no high-grade history in 25 years.	Stop at age 65 if adequate negative prior screening (defined as 2 consecutive negative primary hrHPV tests or 2 consecutive negative cotests within the last 10 years, with the most recent within 5 years) and no history of CIN2+ in the last 25 years.

The evidence driving these changes includes robust longitudinal studies confirming the superior sensitivity and negative predictive value of primary hrHPV testing over cytology, large trials demonstrating the validity of self-collected samples with specific assays for detecting CIN2+, and modeling studies showing improved safety and efficiency with the shift to primary HPV testing and the age 25 start.

Topic-by-Topic Recommendations

• Aged 21-24: Routine screening is not recommended. Exceptions include individuals with HIV or immunosuppression, or those who began screening before 25 per prior guidelines. For these individuals, screening is cytology-based every 3 years; primary hrHPV testing is not recommended.
• Aged 25-65 (Average Risk): Screen with primary hrHPV testing every 5 years. Self-collection using FDA-approved/validated assays and processes is endorsed as an option. Cytology alone or cotesting are no longer routine options.
• Management of Results (Primary HPV):
  • Negative hrHPV: Return to routine screening in 5 years.
  • Positive hrHPV 16/18: Refer for immediate colposcopy.
  • Positive hrHPV (Other 12 Types): Reflex to cytology. If cytology negative (or ASC-US), repeat hrHPV test in 1 year. If positive again, refer to colposcopy. If cytology is ASC-H, HSIL, or AGC, refer to colposcopy.
• Aged >65: Discontinue screening if:
  • No history of CIN2+ within the past 25 years, AND
  • Adequate prior negative screening (e.g., 2 consecutive negative primary hrHPV tests within 10 years, most recent within 5 years; or 2 consecutive negative cotests within 10 years, most recent within 5 years).

  Screening should continue beyond 65 for those not meeting cessation criteria.

• Post-Hysterectomy (without cervix): Do not screen unless history of CIN2+ or cervical cancer.
• Special Populations (HIV, Immunocompromised): Follow separate, more intensive guidelines (e.g., HIV: Start screening at 21, continue beyond 65, use cotesting or annual primary HPV).

The recommendations are graded based on strong evidence (A or B recommendations) for the core screening strategies and intervals.

Expert Commentary and Insights

The ACOG Committee Opinion emphasizes qualified support for the WPSI guidelines, particularly highlighting crucial considerations for implementing self-collection: “While self-collection presents a transformative opportunity to reach underserved populations and overcome barriers to screening, its success hinges on validated laboratory assays, robust patient education on proper technique, and seamless integration within healthcare systems to ensure timely follow-up of positive results,” states the committee. Experts largely agree that the shift to exclusive primary HPV testing is evidence-based and simplifies screening protocols. Key controversies and discussion points include:

• Self-Collection Implementation: Concerns center on workflow integration (lab processing, ordering, billing), ensuring patient comprehension, and managing results/follow-up effectively.
• Age 25 Start: While data supports this, some clinicians express caution about potential missed cases in very high-risk young adults, emphasizing the critical role of HPV vaccination in this context.
• Resource Allocation: Experts stress that the savings from reduced screening frequency should be redirected into improving HPV vaccination rates and ensuring equitable access to primary HPV testing and self-collection kits.

Future research needs include long-term outcomes data for self-collection programs, refining risk prediction models using HPV genotyping and methylation markers, and optimizing strategies for reaching unscreened and under-screened populations.

Practical Implications

These updated guidelines necessitate significant practice changes:

• Clinical Practice: Clinicians must transition away from offering cytology alone or cotesting as routine options for average-risk patients 25-65. They need to implement systems for offering and processing self-collected samples. Patient counseling should emphasize the rationale for the 5-year interval and the safety of stopping at 65 with adequate history.
• Laboratories: Adoption and validation of primary hrHPV testing platforms, including processing protocols for self-collected specimens, is essential.
• Healthcare Systems/Policy: Payers need to update coverage policies to include primary hrHPV testing every 5 years and self-collection kits/support. Public health initiatives must promote HPV vaccination and the new screening options, particularly targeting disadvantaged communities. Systems must ensure reliable follow-up pathways for positive self-collection results.
• Patient Outcomes: Anticipated benefits include increased screening adherence through self-collection, earlier detection of precancerous changes via primary HPV’s sensitivity, and reduced harm from over-screening and unnecessary procedures. The emphasis on validated assays and follow-up protocols is critical to maintain safety.

References

1. Screening for Cervical Cancer. ACOG Committee Statement No. [Number]. Obstetrics and gynecology. 2026 Apr;147(5):eXX-eYY. PMID: 42024877. https://pubmed.ncbi.nlm.nih.gov/42024877/
2. Women’s Preventive Services Initiative (WPSI). Cervical Cancer Screening Final Recommendation Statement. 2026. [Link to WPSI website/publication – specific URL TBD upon publication]
3. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020 Apr;24(2):102-131. PMID: 32243307. (Provides context for management algorithms)
4. Arbyn M, Smith SB, Temin S, et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018 Nov 15;363:k4823. PMID: 30442872. (Key evidence for self-collection)
5. Curry SJ, Krist AH, Owens DK, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Aug 21;320(7):674-686. PMID: 30140884. (Previous major guidelines providing context for evolution – updated USPSTF expected but 2026 WPSI/ACOG is the focus here).
6. Adcock R, Cuschieri K, Wentzensen N, et al. Validation of HPV Genotyping for Triage of Women with Persistent HPV Infections in the FOCAL and Canadian Cervical Cancer Screening Trials. J Clin Microbiol. 2021 Sep 20;59(10):e0105821. PMID: 34346715. (Evidence supporting genotyping in management).